Lenacapavir: A Breakthrough in HIV Prevention Affordability

A new analysis has revealed that lenacapavir, a long-acting injectable for HIV prevention, could be produced for as little as $25 per person per year, potentially transforming global efforts to end the HIV epidemic. The study, co-authored by Andrew Hill and featured in The Lancet, demonstrates that generic production costs are dramatically lower than the current market price of over $28,000 per person annually. This breakthrough has the potential to make lenacapavir a highly cost-effective intervention in the fight against HIV, but only if patent barriers are overcome and the drug is made affordable and widely available.

Key Takeaways:

• Lenacapavir, administered just twice a year, has been shown to reduce HIV transmission to nearly zero.
• The current price of lenacapavir in the US market is over $28,000 per person annually.
• A new analysis estimates that lenacapavir could be manufactured and delivered for $35-$46 per year at a volume of two million treatments annually, and as low as $25 per year if scaled to five to ten million people.
• Gilead Sciences has signed voluntary licenses with only 3 generic manufacturers to supply low-cost lenacapavir to 120 lower-income countries, leaving millions without access to this promising prevention tool.
• Major regions with significant HIV burdens, such as parts of Eastern Europe, Central Asia, and most of Latin American countries, remain excluded from the licensing deals.
• Advocates and experts have described the current pricing as "utterly unaffordable" and a threat to public health.
• Professor Andrew Grulich from the Kirby Institute called Gilead's pricing "absolutely crazy," emphasizing that no health system can afford to implement lenacapavir widely at current prices.

Statistics:

• Current price of lenacapavir in the US market: over $28,000 per person annually.
• Estimated cost of producing lenacapavir: $35-$46 per year at a volume of two million treatments annually, and as low as $25 per year if scaled to five to ten million people.
• Number of people without access to lenacapavir due to licensing deals: millions.
• Number of countries excluded from the licensing deals: parts of Eastern Europe, Central Asia, and most of Latin American countries.

Sources:

• The Lancet article, "Lenacapavir: A high-value HIV prevention option for low-resource settings", co-authored by Andrew Hill et al.
• Press release from the European AIDS Treatment Group.
• Make Medicines Affordable campaign report on the estimated cost of producing lenacapavir.